Sall4 (mouse)
- Known as:
- Sall4 (mouse)
- Catalog number:
- Y213754
- Product Quantity:
- 200ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- Sall4 (mouse)
Related genes to: Sall4 (mouse)
- Gene:
- SALL4 NIH gene
- Name:
- spalt like transcription factor 4
- Previous symbol:
- -
- Synonyms:
- dJ1112F19.1, ZNF797
- Chromosome:
- 20q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-21
- Date modifiied:
- 2019-04-23
Related products to: Sall4 (mouse)
Related articles to: Sall4 (mouse)
- Growth hormone (GH) stimulation tests have limited reliability and may lead to false-positive results. - Source: PubMed
Publication date: 2026/05/07
Plachy LukasDusatkova PetraKavciak LukasAmaratunga Shenali AnneSlavenko MatveiDrabova JanaMaratova KlaraNeuman VitObermannova BarboraKolouskova StanislavaSnajderova MartaSumnik ZdenekLebl JanPruhova Stepanka - Hepatoid adenocarcinoma of the stomach (HAS) is a rare form of gastric cancer. This study assessed the impact of tumor node metastasis (TNM) stage on survival in HAS compared with non-HAS patients, identified prognostic factors, and developed a predictive nomogram. - Source: PubMed
Publication date: 2026/05/23
Tong ShanXu BoqiYe XiangYin JunHu Hao - Hepatoid adenocarcinoma (HAC) of the biliary tract is an exceptionally rare malignancy with substantial diagnostic challenges. We performed a descriptive clinicopathologic study of 9 institutional cases supplemented by a literature review of 34 previously reported cases. The institutional cohort underwent centralized histopathologic review, immunohistochemical analysis, and molecular profiling. Across the combined cohort (n = 43), tumors arose in the gallbladder (n = 27) and bile ducts (n = 16), with a female predominance (male-to-female ratio, 0.56), mean age of 68.4 years, and distant metastases in 39% of patients. Within the institutional cohort, Glypican-3 and SALL4 showed the highest sensitivity among tested markers, exceeding HepPar-1 and alpha-fetoprotein. Histologic heterogeneity was frequent, and two mixed hepatoid-enteroblastic tumors demonstrated shared mutational profiles supporting a common clonal origin. One longitudinally sampled case showed genomic and immunophenotypic changes during metastatic progression. These findings expand the limited literature on biliary HAC and support a morphologically heterogeneous disease spectrum, with Glypican-3 and SALL4 serving as useful adjunctive markers. - Source: PubMed
Publication date: 2026/04/28
YuLu FengYing ZhouJing Xu - Intracranial germ cell tumors (iGCTs) are rare neoplasms that predominantly affect children and adolescents, accounting for up to 20% of pediatric germ cell tumors and showing higher incidence in East Asian populations. These tumors commonly arise in the pineal and suprasellar regions, with a subset presenting as bifocal lesions. iGCTs are broadly classified into germinomas and non-germinomatous germ cell tumors (NGGCTs), with germinomas representing two-thirds of cases. Tumor classification reflects their developmental origin from primordial germ cells and is confirmed through histopathology and immunohistochemistry, notably with markers, such as SALL4, PLAP, OCT3/4, and CD117. NGGCTs include embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratomas and often secrete tumor markers like alpha-fetoprotein (AFP) and beta-hCG, which guide diagnosis and treatment without biopsy. Accurate diagnosis using imaging, markers, with or without histology, followed by risk-adapted therapy, is crucial for optimizing outcomes in this heterogeneous group of CNS tumors Treatment strategies differ significantly between tumor types. Germinomas, highly radiosensitive, are treated with chemotherapy and reduced-field radiotherapy, while NGGCTs require intensive chemotherapy, surgical resection of residual tumor, and high-dose radiotherapy. Prognosis is excellent for germinomas but remains more guarded for NGGCTs. Long-term follow-up is essential due to the risk of recurrence and treatment-related sequelae. - Source: PubMed
Faure Conter Cecile - We reported a case of pulmonary blastoma treated with surgical resection, in which we analyzed the clinical features, pathological characteristics, diagnosis, differential diagnosis, treatment, and prognosis. The clinical features, histopathology, and immunohistochemical staining results were observed, along with perioperative adjuvant therapy. The patient, a 21-year-old female, was admitted with the chief complaint of "lung mass discovered during physical examination for over one year." PET-CT revealed a metabolically active soft tissue mass measuring 7.8 cm×8.4 cm in the right lower lobe, with hypermetabolic right hilar lymph nodes suggestive of metastasis. Both biopsy and postoperative pathology confirmed pulmonary blastoma. Immunohistochemistry showed: AE1/AE3 (+), CK7 (-), CK20 (-), TTF-1 (+), NapsinA (focal+), SALL4 (+), ER (-), Desmin (-), MyoD1 (-), S-100 (focal+), B-Catenin (+), SYN (partial+), CgA (focal+), Ki-67 (40%+). Grossly, the tumor presented as an oval-shaped, grayish-yellow mass measuring 8.5 cm×6.8 cm×6.0 cm, with a brittle texture and relatively well-demar boundaries from surrounding tissues. Bronchial margins and pleura were not involved. Microscopically, the tumor consisted of varying proportions of epithelial and mesenchymal components. The epithelial component typically exhibited low-grade embryonic-type adenocarcinoma morphology, with morule-like squamous cell nests. The stromal cells displayed primitive mesenchymal morphology. The patient achieved a favorable outcome after comprehensive treatment consisting of neoadjuvant immunochemotherapy, radical surgery, and adjuvant immunotherapy maintenance. Pulmonary blastoma is a rare and highly malignant lung tumor. It should be distinguished from carcinosarcoma, adenocarcinoma, and other lung neoplasms. The primary treatment is surgical resection. Chemotherapy and immunotherapy should be considered as potential therapeutic strategies for pulmonary blastoma. - Source: PubMed
Zhang NZhang W LGe Y NZhang YJiang J GShi J